Biotech Values

[bellweather1]

Well, I'm glad you asked the question, because I assume you(and numerous others)know a whole heck of lot more than I do about the internecine working of biotech/heathcare COs.,

and I'd appreciate whatever feedback you or other people can supply.

But, my understanding, from the beginning, has been that if you become a shareholder of this co, you have signed on to the Michael Weiss Show(for better or worse), and that's it.

Assuming his clinical judgment continues to be good(as it appears to have been so far), and his financial interests as a lead shareholder are tied up with the COs increase in market cap, it's not obvious to me(apart and aside from his selling stock), what I should be concerned about.

So please advise me of any scenarios that would be concerning that shareholders should be on the lookout for, or, what is more likely to occur in the "minority shareholder" context you've outlined, vs the alternative.

The only thing I can think of is that he sells the company for too cheap a face value price, while structuring some side arrangement which benefits the insiders disproportionately.

Are you aware of what such an arrangement might look like? Can you think of any examples?

TIA,

bw